Varian places RT units; offers storage system

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 18 No 2
Volume 18
Issue 2

Varian Medical Systems, of Palo Alto, Calif., has installed new radiotherapy units at multiple sites worldwide:

Varian Medical Systems, of Palo Alto, Calif., has installed new radiotherapy units at multiple sites worldwide:

• Novalis Tx image-guided stereotactic body radiation therapy and radiosurgery platform at Oregon Health & Science University in Portland.

• Novalis Tx radiosurgery platform at Tata Memorial Hospital in Mumbai, India.

• RapidArc radiotherapy systems at Innovative Cancer Institute in South Miami, Fla., at Trinitas Comprehensive Cancer Center in Elizabeth, N.J., and at Sudharz Krankenhaus in Nordhausen, Germany.

• Clinac DHX at North Estonia Regional Hospital in Tallinn, Estonia.

In other news, at RSNA 2008 in Chicago, Varian released OncoView, an oncology-specific image management and storage system. OncoView is designed to supplement a hospital’s existing PACS.

Articles in this issue
Consortium advances multidisciplinary program for colon cancer
Celator joins leukemia society for phase II trial of CPX-351
Genzyme nabs FDA approval for stem cell mobilizing agent
FDA launches pilot safety program for foreign drugs
Radiation oncology society adopts new moniker
Varian places RT units; offers storage system
Improvements in Pap screenings proposed
New outlook for neuroendocrine cancer
Elderly multiple myeloma patients remain responsive to novel therapy teamed with conventional treatment
Mismatched cord blood stem cells meet need for urgent Rx in acute leukemia
Risk of transplantrelated mortality doesn’t increase with cord blood
NSABP B-30: Amenorrhea relates to survival
Easy methods curtail toxins in food linked to cancer in Africa
Growth of Medicare HMOs could impact clinical trials
Trastuzumab in the adjuvant setting: Is concurrent treatment better than sequential?
Recent Videos
Select comorbidities, ECOG status, and the receipt of radiation were among the differences between a real-world cohort and the RUBY trial population.
Related Content
Phase 2 data may support atezolizumab plus chemotherapy as a treatment option in advanced or recurrent thymic carcinoma.

Atezolizumab/Chemotherapy May Show Meaningful Activity in Thymic Carcinoma

Russ Conroy
March 21st 2025
Article

Phase 2 data may support atezolizumab plus chemotherapy as a treatment option in advanced or recurrent thymic carcinoma.

Low grade serous ovarian cancer, a rare epithelial ovarian cancer subtype, requires differentiated treatment from its high-grade counterpart.

Redefining the Treatment Paradigm in Low Grade Serous Ovarian Cancer

Kathleen N. Moore, MD, MS
March 17th 2025
Podcast

Low grade serous ovarian cancer, a rare epithelial ovarian cancer subtype, requires differentiated treatment from its high-grade counterpart.

FDA Approves PET Imaging Agent for Prostate Cancer

FDA Approves PET Imaging Agent for Prostate Cancer

Ariana Pelosci
March 21st 2025
Article

The new drug application for TLX007-CDx has been approved by the FDA for patients with prostate cancer.

Oncologists Reflect on Pandemic's Lasting Impact on Cancer Care

Oncologists Reflect on Pandemic's Lasting Impact on Cancer Care

Aditya Bardia, MD, MPH;Ritu Salani, MD;Scarlett Lin Gomez, PhD;Marwan G. Fakih, MD;Elizabeth Ren Zhang-Velten, MD, PhD;Frances Chow, MD;James B. Yu, MD, MHS, FASTRO
March 10th 2025
Podcast

Hear from leading cancer experts about the lasting impact the COVID-19 pandemic has left on clinical practice.

Durvalumab Does Not Surpass Cetuximab in Head and Neck Cancer

Durvalumab Does Not Surpass Cetuximab in Head and Neck Cancer

Ariana Pelosci
March 20th 2025
Article

Christina Henson, MD, discusses recent phase 3 trial results comparing durvalumab to cetuximab in head and neck cancer, and why the trial was stopped early.

Timely guideline-concordant care may mitigate racial and ethnic disparities in overall survival among patients with inflammatory breast cancer.

Data Show Guideline-Concordant Care Gaps in Inflammatory Breast Cancer

Russ Conroy
March 20th 2025
Article

Timely guideline-concordant care may mitigate racial and ethnic disparities in overall survival among patients with inflammatory breast cancer.